PHARMACIELO LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.155 CAD | -3.12% |
|
-13.89% | -13.89% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2021 | 1.94 2.67 | Sales 2022 | 5.31 7.3 | Capitalization | 26.5M 36.44M |
|---|---|---|---|---|---|
| Net income 2021 | -26M -35.75M | Net income 2022 | -14M -19.25M | EV / Sales 2021 | 76,397,769 x |
| Net Debt 2021 | 2.8M 3.85M | Net Debt 2022 | 12.26M 16.86M | EV / Sales 2022 | 7,301,159 x |
| P/E ratio 2021 |
-5.36
x | P/E ratio 2022 |
-1.82
x | Employees | - |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 91.54% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -3.13% | ||
| 1 week | -13.89% | ||
| Current month | -13.89% | ||
| 1 month | -41.51% | ||
| 3 months | -6.06% | ||
| 6 months | -13.89% | ||
| Current year | -13.89% |
1 week
0.16
0.19
1 month
0.150.28
Current year
0.130.29
1 year
0.110.29
3 years
0.111.70
5 years
0.118.59
10 years
0.1111.50
| Managers | Title | Age | Since |
|---|---|---|---|
Marc Lustig
CEO | Chief Executive Officer | 51 | 20-11-19 |
Ian Atacan
DFI | Director of Finance/CFO | - | 21-06-06 |
| Chief Tech/Sci/R&D Officer | - | 22-07-24 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Douglas Bache
BRD | Director/Board Member | - | 19-01-14 |
Marc Lustig
CEO | Chief Executive Officer | 51 | 20-11-19 |
William Nicholas
BRD | Director/Board Member | - | 21-08-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-07 | 0.155 | -3.13% | 85,204 |
| 24-05-06 | 0.16 | -8.57% | 108,500 |
| 24-05-03 | 0.175 | 0.00% | 14,000 |
| 24-05-02 | 0.175 | -5.41% | 70,205 |
| 24-05-01 | 0.185 | +2.78% | 92,598 |
Delayed Quote Toronto S.E., May 07, 2024 at 10:29 am EDT
More quotes
PharmaCielo Ltd. is a Canada-based company with a focus on ethical and sustainable processing and supplying of all natural, pharmaceutical-grade medical cannabis products to channel distributors. The Company has two subsidiaries, PharmaCielo Colombia Holdings S.A.S. (PharmaCielo Colombia) and Ubiquo Telemedicina S.A.S. (Ubiquo). PharmaCielo Colombia cultivates and processes the Companyâs all-natural cannabis into standardized, medicinal-grade oil extracts and related products. In Colombia, PharmaCielo Colombia is a licensed cultivator, producer, and distributor of both TetraHydroCannabinol (THC) and Cannabidiol (CBD) medical cannabis for use in Colombia, international export, and research purposes. Ubiquo is a knowledge management and medical consultation system that focuses on creating access to healthcare for Colombians. Ubiquo is a technology platform and a user interface that allows doctors and patients to communicate. Ubiquo is used as a communication tool.
Sector
Pharmaceuticals
Calendar
2024-05-26
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -13.89% | 19.21M | |
| +43.96% | 6.34B | |
| -15.56% | 4.51B | |
| -6.52% | 3.29B | |
| +5.47% | 3.2B | |
| -0.76% | 2.59B | |
| +56.34% | 2.09B | |
| -4.11% | 1.76B | |
| +2.93% | 1.7B | |
| -8.02% | 1.62B |
- Stock Market
- Equities
- PCLO Stock